Skip to main content
    Investor Information
    Welcome to NanoViricide's Investor Relations section.
    NanoViricides, Inc. is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology permits direct attacks at multiple points on a virus particle. It is believed that such actions lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.
    We have been aggressively expanding our portfolio of virus targets and drug candidates every year since our inception in May, 2005.
      October 8, 2026
    NV-387, A Broad-Spectrum Antiviral Presenting A Revolutionary Strategy for Viral Infections
      September 24, 2026
    Phase 2 Clinical Trial For HV-387 In MPox Begins
      July 14, 2026
    NanoViricides Announces Phase 2 Ebola Trial Approval and Prepares Next Regulatory Filing
      July 7, 2026
    Novel Technology With Broad-Spectrum Antiviral Applications In Development

      June 8, 2026
      December 17, 2025
    Optimizing broad-spectrum nanoviricides as a treatment for viral infections – Initiate with a Buy
     November 11, 2025
      2025-11-08 Annual Meeting Presentation
     November 10, 2025
    NNVC: Getting Set for Phase 2 Trial of NV-387 in MPox... 

     Sept 30, 2025
     September 8, 2025
     CEO Chat with Anil Diwan, President & Executive Chairman at NanoViricides, Inc.
     February 28, 2025 
     September 20, 2024
     May 7, 2024
     December 13, 2023
      December 12, 2023

    Press Releases